Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yan Shang
Institutions:
Fudan University,
Fudan University Shanghai Cancer Center,
State Key Laboratory of Genetic Engineering
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
Pudong Medical Center,
State Key Laboratory of Genetic Engineering
ORCID:
0009-0007-2631-6256
Observed ORCID:
0009-0007-2631-6256
OpenAlex ID:
A5090075714
The single cell immunogenomic landscape after neoadjuvant immunotherapy combined chemotherapy in esophageal squamous cell carcinoma
2024
·
Zheyi Wang
, Yue Zhao
, et al.
·
Cancer Letters
·
24
The impact of station 4L lymph node dissection on short-term and long-term outcomes in non-small cell lung cancer
2022
·
Yang Wo
, Hang Li
, et al.
·
Lung Cancer
·
14
LncRNA TMEM99 Complexes with IGF2BP2 to Inhibit Autophagy in Lung Adenocarcinoma
2025
·
Zhigang Wu
, Yue Zhao
, et al.
·
Advanced Science
·
9
PDF
Individualized prediction of survival benefit from postoperative radiotherapy for patients with malignant pleural mesothelioma
2023
·
Yang Wo
, Yizhou Peng
, et al.
·
Cancer Medicine
·
1
PDF
Targeting PRPF19 suppresses lung cancer progression by abrogating cytokinesis and potentiating anti-tumor immunity
2026
·
Shuaihu Li
, Longfu Zhang
, et al.
·
Cell Death and Disease
PDF
Data from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
Figure S2 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S1 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S5 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S3 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S6 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Figure S7 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Table S3 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
Figure S4 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
PDF
Table S2 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
Table S1 from An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
An Optimized Platform Overcomes Excessive Tumor Immune Rejection Induced by the CRISPR/Cas9 Lentiviral System
2025
·
Yan Shang
, Shuaihu Li
, et al.
·
Cancer Research
Show more works
View as search
Works count:
17
Citation count:
48
H-index:
3
I10-index:
2
Year
Topic
Type